Famous for their role in combating the COVID-19 pandemic, mRNA therapeutics will not be limited in scope to vaccines. mRNA technology promises the ability to introduce complex proteins to a patient while bypassing potential hazards associated with genome integration. Applications for mRNA are potentially far-reaching, from creating novel treatments for incurable inherited diseases to developing sequence-specific targeted cancer therapies.
The biopharmaceutical industry is rapidly building infrastructure for the development and manufacturing of mRNA therapeutics with a need for rigorous process and quality controls. mRNA is an unstable molecule, requiring extensive validation prior to tech transfer to cGMP manufacturing. Analytical methods developed for assessing in vitro reaction success and downstream processing steps must be scalable to a production environment. Improper documentation of methods and the use of different analytical equipment may require costly and time-consuming rework and revalidation.
Our Danaher Life Sciences companies provide a wide range of analytical solutions and fit-for-purpose technologies to accelerate mRNA development. We enable seamless tech transfer to manufacturing and offer flexible technologies for both upstream and cGMP environments.
mRNA Solutions
To learn more about mRNA solutions from Danaher Life Sciences companies visit:
mRNA Development and Manufacturing
RNA therapies continue to challenge the central tenets of how to treat diseases; however, mRNA development and characterization are not always simple. View Solution